Novel omalizumab liquid formulation bioequivalent to lyophilized formulation Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Comparison of two valved holding chambers for the delivery of an HFA-based solution corticosteroid formulation Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Stability of a new formulation of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003
Delivery of a suspension corticosteroid formulation by small volume nebulizers: a comparative bench study Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Mepolizumab self-administration via autoinjector and prefilled syringe: the qualitative patient experience Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Estimation of efficiency of new combined preparation built-in-liposomes budesonide compared with water budesonide suspension Source: Eur Respir J 2004; 24: Suppl. 48, 83s Year: 2004
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
A breath-actuated jet nebulizer (BAN) has dosimetric capability for a suspension formulation based on differing volume fill of medication as well as run time Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Reduction in nebulisation time of aqueous drug solutions by the eFlow rapid in comparison to a jet nebuliser to improve patient convenience and compliance Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005